Twin Capital Management Inc. Takes $916,000 Position in Ralliant Corporation $RAL

Twin Capital Management Inc. bought a new position in shares of Ralliant Corporation (NYSE:RAL) in the first quarter, HoldingsChannel reports. The fund bought 22,022 shares of the company’s stock, valued at approximately $916,000.

Several other large investors have also recently bought and sold shares of RAL. Principal Financial Group Inc. lifted its holdings in Ralliant by 2.0% during the 1st quarter. Principal Financial Group Inc. now owns 546,560 shares of the company’s stock worth $22,731,000 after buying an additional 10,592 shares during the last quarter. Fifth Third Bancorp increased its holdings in shares of Ralliant by 3,988.0% in the 1st quarter. Fifth Third Bancorp now owns 32,132 shares of the company’s stock valued at $1,336,000 after acquiring an additional 31,346 shares during the last quarter. Moran Wealth Management LLC acquired a new stake in shares of Ralliant during the 1st quarter worth about $227,000. Counterpoint Mutual Funds LLC acquired a new stake in shares of Ralliant during the 1st quarter worth about $855,000. Finally, Canoe Financial LP lifted its stake in Ralliant by 6.6% during the first quarter. Canoe Financial LP now owns 118,622 shares of the company’s stock worth $4,933,000 after purchasing an additional 7,319 shares during the last quarter.

Ralliant Trading Down 0.8%

NYSE:RAL opened at $66.99 on Friday. The company has a market capitalization of $7.50 billion and a PE ratio of -6.12. Ralliant Corporation has a 52-week low of $37.27 and a 52-week high of $75.41. The stock’s 50 day moving average price is $64.75 and its 200 day moving average price is $53.01. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The company had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, research analysts anticipate that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were paid a dividend of $0.05 per share. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant’s dividend payout ratio is currently -1.83%.

Analyst Ratings Changes

Several equities analysts have commented on RAL shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Barclays upped their target price on shares of Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a report on Wednesday, May 13th. Evercore began coverage on shares of Ralliant in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 target price on the stock. Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Finally, Citigroup boosted their price target on shares of Ralliant from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $70.80.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.